Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy.
In advanced chronic myeloid leukaemia patients, STI-571 produces complete haematological response in most cases and cytogenetic response in up to 50%. However, these patients often suffer periods of pancytopenia, which can lead to life-threatening complications, and is probably due to the small number of residual normal stem cells. We have re-infused peripheral blood stem cells collected at diagnosis, in a patient, while maintaining STI-571 treatment. The patient recovered from aplasia, with Philadelphia-negative haematopoiesis. Discontinuing an effective treatment because of persistent aplasia is a major concern; this method circumvents this problem inpatients who have undergone a stem cell harvest at diagnosis.
Lewalle
Philippe
P
Department of Haematology, Institut Bordet, University of Brussels, Belgium.
Meuleman
Nathalie
N
Verhest
Alain
A
Bron
Dominique
D
Martiat
Philippe
P
D001549:Benzamides; D003131:Combined Modality Therapy; D015925:Cryopreservation; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000601:surgery*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D014182:Transplantation, Autologous
D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C426236:ARG tyrosine kinase; D011505:Protein-Tyrosine Kinases